Takeda To Cut Jobs In Face Of Slowing Sales, Loss Of Actos Patent Protection By: J Poole | - Los Angeles, CA, January 20, 2012 Takeda Pharmaceuticals, Japans largest pharmaceutical company and maker of popular Type 2 diabetes drug Actos, is expected to cut its global workforce by as much as 10% through 2015. According to a Chicago Tribune article, the move is intended to offset decreased sales caused by a slow economy and projected losses in revenue when generic forms of Actos are expected to hit the market later this year.
One common debate is whether diabetes medications increase the risk of heart disease. The Food and Drug Administration (FDA) requires oral diabetes medicines to carry a warning regarding increased risk of heart attack.
Several studies have associated a diabetes drug, Rosiglitazone, with cardiovascular mortality and morbidity. Rosiglitazone belongs to a class of anti-diabetic drugs knows as thiazolidinediones. The generic name ... Tags:diabetic drugs, diabetes, type2 diabetes, heart disease
Antihypertensives Market To 2016 By: GBI Research | - In 2009, the global anti-hypertensive market was estimated to be worth $27.2 billion, representing a Compound Annual Growth Rate (CAGR) of 5.0% between 2002 and 2009. The market is forecast to reach $30 billion by 2016, indicating a CAGR of 1.5% between 2009 and 2016. The primary reason for slight and gradual growth in the market is the patent expiries of major blockbusters, which are expected to decrease the annual cost of therapy after 2007.
